Systematic review: cardiovascular safety profile of 5-HT4 agonists developed for gastrointestinal disorders
Review article: coeliac disease, new approaches to therapy
Randomised clinical trial: efficacy of a new synbiotic formulation containing Lactobacillus paracasei B21060 plus arabinogalactan and xilooligosaccharides in children with acute diarrhoea
Predictors of severe outcomes associated with C lostridium difficile infection in patients with inflammatory bowel disease
Chronic obstructive pulmonary disease: an independent risk factor for peptic ulcer bleeding: a nationwide population-based study
Control of intra-oesophageal pH in patients with Barrett's oesophagus on omeprazole-sodium bicarbonate therapy
A comparison of the acid-inhibitory effects of esomeprazole and rabeprazole in relation to pharmacokinetics and CYP2C19 polymorphism
Endoscopic evaluation of the gastro-duodenal tolerance of short-term analgesic treatment with 25 mg diclofenac-K liquid capsules
Functional dysbiosis within the gut microbiota of patients with constipated-irritable bowel syndrome
Commentary: coeliac disease, mortality and malignancy
Commentary: coeliac disease, mortality and malignancy – authors’ reply
Commentary: HBsAg levels as predictor of sustained response to peg interferon in HBeAg-negative chronic hepatitis B
Commentary: HBsAg levels as predictor of sustained response to peginterferon in HBeAg-negative chronic hepatitis B – author's reply
Commentary: effect of pregabalin on acid-induced oesophageal hypersensitivity
Commentary: ursodeoxycholic acid as chemoprevention in inflammatory bowel disease and primary sclerosing cholangitis
Commentary: ursodeoxycholic acid as chemoprevention in inflammatory bowel disease and primary sclerosing cholangitis – authors’ reply
Commentary: BMI and the need for adalimumab dose escalation in Crohn's disease
Commentary: BMI and the need for adalimumab dose escalation in Crohn's disease – authors’ reply
Commentary: short-term stability of subtypes in the irritable bowel syndrome
Commentary: short-term stability of subtypes in the irritable bowel syndromes – authors’ reply
Letter: the ethics of using inferior regimens in H. pylori randomised trials
Letter: the ethics of using inferior regimens in H. pylori randomised trials – invited comment
Letter: the ethics of using inferior regimens in H. pylori randomised trials – invited comment
Letter: the ethics of using inferior regimens in H. pylori randomised trials – editors’ reply
Letter: identication of probiotics by specific strain name
Letter: identification of probiotics by specific strain name – author's reply
Letter: liver dysfunction and survival in hepatocellular carcinoma treated by transarterial chemoembolisation
Letter: liver dysfunction and survival in hepatocellular carcinoma treated by transarterial chemoembolisation – authors’ reply
Corrigenda
Corrigenda